Nifedipine is a dihydropyridine calcium channel blocker indicated for the management of several subtypes of angina pectoris, and hypertension. Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to nicardipine.
- Mechanism
- Curator reviewed · 3 references
Nifedipine blocks voltage gated L-type calcium channels in vascular smooth muscle and myocardial cells. This blockage prevents the entry of calcium ions into cells during depolarization, reducing peripheral arterial vascular resistance and dilating coronary arteries. These actions reduce blood pressure and increase the supply of oxygen to the heart, alleviating angina.
- Primary indication
- Nifedipine capsules are indicated to treat vasospastic angina and chronic stable angina.Curator reviewed · 12 structured indications
- Formula / weight
- C17H18N2O6 · 346.3346 g/mol (avg)
- First approval
- Canada, 1995 · United States, 1981
- Code names
- BAY A 1040
- Brand names
Resolves to
HYIMSNHJOBLJNT-UHFFFAOYSA-NSMILESCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCWhat you can answer from here — as of September 20, 2026
Which drugs share a target with Nifedipine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account